Coherent Inc. (2022) integration

The July 1, 2022 acquisition of legacy Coherent Inc. ($7.01B consideration, ultimately renamed-to entity) is the largest single transaction in II-VI / Coherent’s corporate history. It set the capital structure that has dominated the FY2023–FY2026 deleveraging cycle and underpinned the rebrand to “Coherent Corp.” on September 8, 2022 (NOT Sept 1 — corrected per primary-source verification). Understanding the 2022 integration is foundational to reading the FY2026 balance sheet and the pre-NVDA leverage profile.

Transaction structure

Term	Value
Target	Coherent Inc. (legacy industrial-laser leader, 1966 founding)
Bidding race	II-VI vs Lumentum vs MKS Instruments (Lumentum’s $7.03B counter was the upper bid; II-VI prevailed via better strategic-fit and certainty-of-close terms)
Termination fee collected from prior bidder	$217.6M
Final transaction value	$7.01B in cash + stock consideration
Closing date	July 1, 2022
Antitrust	HSR clearance + multi-jurisdictional antitrust reviews
Renaming	September 8, 2022 — combined entity rebranded “Coherent Corp.” (retained NYSE COHR ticker; CIK unchanged 0000820318)

Financing components

The $7.01B consideration was funded via a multi-instrument financing stack:

Instrument	Approximate amount	Notes
Common-stock consideration to Coherent Inc. shareholders	~$1.4B	New II-VI common shares issued to Coherent Inc. holders
Cash to Coherent Inc. shareholders	~$5.6B	Funded via debt + preferred + cash on hand
Term Loan A + Term Loan B (banks)	~$3.0B+	Multi-tranche bank facility
Senior Notes (5.00% due 2029)	~$990M	Senior unsecured notes
Series A 6.00% Mandatory Convertible Preferred	~$575M	Public, SEC-registered; matured / converted July 2023
Series B Convertible Preferred (Bain Capital alone via BCPE Watson SPV)	up to $2.0B	Privately-placed preferred equity; B-1/B-2/B-3 sub-tranches; optional conversion at $85.00; 5.00% PIK through year four
Cash on hand contribution	~$200–400M	II-VI pre-deal cash + working capital

Source: II-VI / Coherent Bain Capital terms press release March 16, 2021 ✓; SEC filings via EDGAR ✓.

Series B Bain Capital preferred — load-bearing instrument

The largest piece of the financing puzzle is the Series B Convertible Preferred Stock private placement to Bain Capital alone, via the BCPE Watson SPV (special-purpose vehicle). Senator Investment Group is sometimes cited in press summaries but is not a holder of this instrument. Key terms:

Feature	Term
Aggregate authorized face	Up to $2.0B (Bain Capital alone via BCPE Watson; funded incrementally)
Series structure	Series B (B-1, B-2, B-3 sub-tranches with different funding dates)
Optional conversion strike	$85.00 per common share (holder-elected; not mandatory)
Dividend	5.00% PIK (paid-in-kind) through year four; cash-pay step thereafter (waived November 2025 — see below)
Conversion mechanic	Holder option (not mandatory; no scheduled mandatory date)
Voting rights	As-converted basis with common (subject to limits)
Post-2022 leverage profile	Designed to keep post-close balance sheet at ~3.8× EBITDA

Verified-fact corrections vs prior internal drafts:

Holder is Bain Capital alone via BCPE Watson SPV — Senator Investment Group is NOT a holder despite frequent media conflation.

Conversion is optional at a single $85.00 strike — earlier drafts that listed B-1 $85.00 / B-2 $104.09 / B-3 $93.58 referenced funding-tranche reset levels rather than the headline conversion economics.

Dividend is 5.00% PIK through year four, not a cash high-single-digit coupon. PIK accrues to face, magnifying the in-the-money common-equivalent base over time (until the November 2025 waiver halted accrual).

The instrument is Convertible Preferred (optional), NOT a Mandatory Convertible. Source: II-VI / Bain Capital terms press release March 16, 2021 ✓.

November 2025 Bain Capital dividend waiver

A material structural change: on November 20, 2025, Coherent and Bain Capital entered a Waiver Agreement — Bain irrevocably and unconditionally waived all rights to receive dividends on any shares of the Series B Preferred Stock from that point forward (Investing.com 8-K summary) ✓.

The strategic implications:

PIK accretion stops growing the convertible base — the as-converted dilution overhang is now fixed at the existing PIK-accreted face rather than expanding for the remainder of the four-year PIK window.
Post-year-four cash-pay obligation eliminated — the cash-pay step that would have begun once the PIK window expired is permanently waived, removing a future operating-cash-flow drag.
Bain economics shift to common-equity-equivalent — coupon-bearing preferred becomes common-stock-equivalent upside via eventual conversion.
Alignment with common shareholders — Bain’s new economics are aligned with COHR equity holders (vs the historical preferred-extracting structure).

This is a bullish signal on Bain’s view of Coherent’s long-term value — Bain would not waive a structural coupon if it expected mediocre common-stock returns. With COHR ~$305 vs the $85.00 conversion strike, the Series B is roughly 3.6× ITM, and the waiver effectively converts Bain’s economic exposure into a permanent common-equivalent stake without forcing actual conversion.

Public Series A 6.00% Mandatory Convertible Preferred — MATURED 2023

The other 2022 preferred instrument was public and is no longer outstanding:

Feature	Term
Aggregate	Approximately $575M
Coupon	6.00% cash dividend
Mandatory conversion	July 1, 2023 (one-year anniversary of Coherent Inc. acquisition close)
Status as of 2026	Converted to common; no longer outstanding
Source	Preferred Stock Channel — IIVI 6.00% Mandatory Convertible page ✓

The Series A converted to common on July 1, 2023, contributing to share-count expansion but eliminating the cash-dividend drag.

Acquisition rationale and strategic fit

The 2022 acquisition rationale combined four elements:

Industrial-laser scale — combined entity became the leading global industrial-laser supplier (vs IPG Photonics, Trumpf), with a deeper SKU portfolio than either standalone.
Life-sciences expansion — Coherent Inc. brought the genomics-sequencing instrumentation business and bioimaging franchise that II-VI lacked.
Brand recognition — “Coherent” was a more recognizable industrial brand than “II-VI,” supporting the September 2022 rebrand decision.
Cost synergies — facility consolidation, shared services, procurement integration; targeted run-rate synergies of ~$250M annually within 36 months.

The first three rationales were structurally correct. The cost-synergy realization has been on-pace but not above-pace; specific synergy run-rate disclosures have been incremental rather than headline.

Post-close deleveraging trajectory

The post-close leverage profile (~3.8× EBITDA) was elevated. The deleveraging trajectory through FY2023–FY2026:

Period	Total debt ($B)	Adjusted EBITDA ($B)	Leverage
FY2023 (Jul 2022 close)	~$4.5	~$1.0	~4.5×
FY2024	~$4.2	~$1.0	~4.2×
FY2025	$3.7	~$1.4	~2.6×
FY2026 H1	$3.4	~$1.6 (annualized)	~2.1×
Post-NVDA pro-forma	~$3.0–3.2 (after potential paydowns)	~$1.8–2.0	~1.6–1.8×

The deleveraging path has been front-loaded: $437M FY2025 paydown + $400M Q1 FY2026 paydown represent over $800M of debt reduction in 18 months. Combined with EBITDA expansion (operating leverage on AI-cycle revenue growth), leverage has compressed from ~4.5× at close to ~2.1× pro-forma. The NVDA $2B equity injection accelerates this further — pro-forma post-NVDA leverage is sub-2× under base-case EBITDA assumptions.

Cost-synergy realization

Year	Synergy run-rate target	Realized (estimate)
FY2023	$50–80M	~$50M
FY2024	$130–180M	~$140M
FY2025	$200–250M	~$200M+
FY2026 (target completion)	$250M run-rate	On-track / partly absorbed in margin uplift

⚠ Synergy figures are estimates based on management commentary; specific run-rate disclosures have been incremental.

The synergies have been realized largely through margin expansion rather than as a separate disclosed line item. The non-GAAP gross margin expansion from 30.9% FY2024 to 37.9% FY2025 is partly synergy-driven (procurement, facility consolidation, shared services) and partly mix-shift / operating-leverage driven.

Stranded acquisition liabilities

Two notable items remain on the balance sheet from the 2022 acquisition:

Acquisition-related intangible amortization — depresses GAAP gross margin and operating margin vs non-GAAP through FY2027–FY2028 amortization tail
Restructuring / integration costs — ongoing through FY2025 and into FY2026; declining run-rate

Cross-link

Balance sheet — current capital structure including Series B-1/B-2/B-3
Finisar integration — the prior 2019 deleveraging baseline
Quarterly trend — margin trajectory through the integration
Capex cycle — capex profile post-acquisition
01_company Coherent Inc. acquisition